Head-to-Head Comparison of BRAF/MEK Inhibitor Combinations Proposes Superiority of Encorafenib Plus Trametinib in Melanoma

SIMPLE SUMMARY: A decade ago, the diagnosis of metastatic melanoma was mostly a death sentence. This has changed since new therapies became widely available in the clinical setting. In addition to checkpoint inhibitors, targeted therapy with BRAF and MEK inhibitors is standard care for BRAF-mutated...

Descripción completa

Detalles Bibliográficos
Autores principales: Schulz, Alexander, Raetz, Jennifer, Karitzky, Paula C., Dinter, Lisa, Tietze, Julia K., Kolbe, Isabell, Käubler, Theresa, Renner, Bertold, Beissert, Stefan, Meier, Friedegund, Westphal, Dana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9564158/
https://www.ncbi.nlm.nih.gov/pubmed/36230853
http://dx.doi.org/10.3390/cancers14194930

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9564158/
https://www.ncbi.nlm.nih.gov/pubmed/36230853
http://dx.doi.org/10.3390/cancers14194930

Ejemplares similares